Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial

Khaled M. Musallam, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Bueno, Jeevan K. Shetty, Frederik Lersch, Barbara Rosettani, Maria Domenica Domenica Cappellini

Blood (2022) 140 (Supplement 1): 5358–5359.

https://doi.org/10.1182/blood-2022-157113

Published: 2022

Journal Articles

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Michele Cavo, Valerio De Stefano, MD, Angel Ramirez Payer, Martin Wiesholzer, Yvonne Tromp, Gaëtan Vanstraelen, Baerbel Schaedlich, Richez Valentine, Sujith Dhanasiri, Elisabeth Kueenburg, Barbara Rosettani, Claire Martin, Stefano Pozzi, Pamela Bacon, Barbara Gamberi

Blood (2019) 134 (Supplement_1): 5580.

https://doi.org/10.1182/blood-2019-124555

Published: 2019

Journal Articles

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Niels Abildgaard, MD PhD, Marie-Christiane Vekemans, Barbara Gamberi, MD, Francesco Di Raimondo, MD, Angel Ramirez Payer, Charalampia Kyriakou, Alain Kentos, Elisabeth Kueenburg, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Margaret Atiba-Davies, Torben Plesner, MD DSc

Blood (2018) 132 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2018-99-111906

Published: 2018

Journal Articles

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Pieter Sonneveld, MDPhD, Katja C. Weisel, Yan Li, Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1847.

https://doi.org/10.1182/blood.V130.Suppl_1.1847.1847

Published: 2017

Journal Articles

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Francesco Di Raimondo, Charalampia Kyriakou, Martin Schmidt-Hieber, Marie-Christiane Vekemans, Ángel Ramírez Payer, Pal Tore Bentsen, Birgitta Lauri, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Torben Plesner, Professor

Blood (2016) 128 (22): 5680.

https://doi.org/10.1182/blood.V128.22.5680.5680

Published: 2016

Journal Articles

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Katja Weisel, MD, Meletios A Dimopoulos, Niels W.C.J. van de Donk, MD PhD, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld

Blood (2016) 128 (22): 3311.

https://doi.org/10.1182/blood.V128.22.3311.3311

Published: 2016

Journal Articles

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Barbara Gamberi, Miguel Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, Roman Hájek, Monique Minnema, Meletios A Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, MD PhD, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonia Di Micco, Pamela Bacon, Igor Blau

Blood (2016) 128 (22): 3331.

https://doi.org/10.1182/blood.V128.22.3331.3331

Published: 2016

Journal Articles

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Karthik Ramasamy, Meletios A. Dimopoulos, Niels W.C.J. van de Donk, Barbara Gamberi, Frank Bridoux, Matthew Streetly, Elisabeth Kueenburg, Barbara Rosettani, Shona Collins, Frederik Lersch, Pamela Bacon, Katja C. Weisel, Pieter Sonneveld, MD PhD

Blood (2015) 126 (23): 374.

https://doi.org/10.1182/blood.V126.23.374.374

Published: 2015

Journal Articles

Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Barbara Gamberi, Charalampia Kyriakou, John Ashcroft, Miguel T. Hernandez, Jo Caers, Gerard Bos, Maria Asunción Echeveste, Christian Berthou, Renato Zambello, Elisabeth Küenburg, Barbara Rosettani, Brooke Ryder-Smith, Igor W. Blau

Blood (2012) 120 (21): 4068.

https://doi.org/10.1182/blood.V120.21.4068.4068

Published: 2012

Journal Articles

Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma

Michele Cavo, MD, Luciano Masini, Igor W. Blau, Miguel T. Hernandez, Renato Zambello, Paolo de Fabritiis, Christian Berthou, Argiris Symeonidis, Jennifer Bird, Javier De La Rubia, Pamela Bacon, Barbara Rosettani, Elisabeth Kueenburg, Neil Minton

Blood (2011) 118 (21): 1867.

https://doi.org/10.1182/blood.V118.21.1867.1867

Published: 2011

Journal Articles

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Adrian Alegre, Albert Oriol-Rocafiguera, Jose García-Laraña, María-Victoria Mateos, Anna Sureda, MD, PhD, Carmen Martínez Chamorro, María Teresa Cibeira, MD, PhD, Robert Knight, MD, Barbara Rosettani

Blood (2010) 116 (21): 3045.

https://doi.org/10.1182/blood.V116.21.3045.3045

Published: 2010

Journal Articles

Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients

Michel Delforge, Igor W. Blau, Miguel T. Hernandez, Roman Hajek, Luciano Masini, Henk Lokhorst, Giacinto La Verde, Laurence Sanhes, Javier De La Rubia, Janine Collins, Barbara Rosettani, Nancy A Brandenburg, Renato Zambello

Blood (2010) 116 (21): 1939.

https://doi.org/10.1182/blood.V116.21.1939.1939

Published: 2010

NARROW

A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only